Cancer Profiling Market

Cancer Profiling Market - Global Industry Assessment & Forecast

Healthcare

# Pages:

141

Base Year:

2022

Apr - 2023

Format:

Report Code:

VMR-2101

Segments Covered

By Technology Immunoassays, Next-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, In-Situ Hybridization, Microarrays, Other Technologies
By Cancer Type Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancer
By Biomarker Type Genomic Biomarker, Protein Biomarker, Other Biomarker
By Application Research Application, Clinical Application
By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Standard License

$ 4299 USD

Multi User License

$ 6599 USD

Enterprise License

$ 6999 USD

Snapshot

Base Year:	2022
Forecast Years:	2023 - 2030
Historical Years:	2017 - 2021
Revenue 2022:	USD 9.4 Billion
Revenue 2030:	USD 19.28 Billion
Revenue CAGR (2023 - 2030):	10.8%
Fastest Growing Region (2023 - 2030)	Asia Pacific
Largest Region (2022):	North America

Customization Offered

Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market Dynamics
Region Level Market Share
Import Export Analysis
Production Analysis
Others Request Customization Speak To Analyst

Executive Dashboard
1. Strategic Imperatives
Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Global Cancer Profiling Market - Segment Analysis
1. Overview
2. Global Cancer Profiling Market, 2016 - 2028 (USD Million)
3. Global Cancer Profiling Market - by Technology
  1. By Immunoassays
  2. By Next-Generation Sequencing
  3. By Polymerase Chain Reaction
  4. By Mass Spectrometry
  5. By In-Situ Hybridization
  6. By Microarrays
  7. By Other Technologies
4. Global Cancer Profiling Market - by Cancer Type
  1. By Breast Cancer
  2. By Lung Cancer
  3. By Colorectal Cancer
  4. By Prostate Cancer
  5. By Melanoma Cancer
  6. By Other Cancer
5. Global Cancer Profiling Market - by Biomarker Type
  1. By Genomic Biomarker
  2. By Protein Biomarker
  3. By Other Biomarker
6. Global Cancer Profiling Market - by Application
  1. By Research Application
  2. By Clinical Application
7. Global Cancer Profiling Market - by region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
8. Market comparative analysis
North America Cancer Profiling Market - Segment Analysis
1. Overview
2. North America Cancer Profiling Market, 2016 - 2028 (USD Million)
3. North America Cancer Profiling Market, by Technology
  1. By Immunoassays
  2. By Next-Generation Sequencing
  3. By Polymerase Chain Reaction
  4. By Mass Spectrometry
  5. By In-Situ Hybridization
  6. By Microarrays
  7. By Other Technologies
4. North America Cancer Profiling Market, by Cancer Type
  1. By Breast Cancer
  2. By Lung Cancer
  3. By Colorectal Cancer
  4. By Prostate Cancer
  5. By Melanoma Cancer
  6. By Other Cancer
5. North America Cancer Profiling Market, by Biomarker Type
  1. By Genomic Biomarker
  2. By Protein Biomarker
  3. By Other Biomarker
6. North America Cancer Profiling Market, by Application
  1. By Research Application
  2. By Clinical Application
7. North America Cancer Profiling Market, by Country
  1. U.S.
    1. U.S. Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. U.S. Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. U.S. Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. U.S. Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  2. Canada
    1. Canada Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. Canada Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. Canada Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. Canada Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  3. Mexico
    1. Mexico Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. Mexico Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. Mexico Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. Mexico Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
Europe Cancer Profiling Market - Segment Analysis
1. Overview
2. Europe Cancer Profiling Market, 2016 - 2028 (USD Million)
3. Europe Cancer Profiling Market, by Technology
  1. By Immunoassays
  2. By Next-Generation Sequencing
  3. By Polymerase Chain Reaction
  4. By Mass Spectrometry
  5. By In-Situ Hybridization
  6. By Microarrays
  7. By Other Technologies
4. Europe Cancer Profiling Market, by Cancer Type
  1. By Breast Cancer
  2. By Lung Cancer
  3. By Colorectal Cancer
  4. By Prostate Cancer
  5. By Melanoma Cancer
  6. By Other Cancer
5. Europe Cancer Profiling Market, by Biomarker Type
  1. By Genomic Biomarker
  2. By Protein Biomarker
  3. By Other Biomarker
6. Europe Cancer Profiling Market, by Application
  1. By Research Application
  2. By Clinical Application
7. Europe Cancer Profiling Market, by Country
  1. Germany
    1. Germany Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. Germany Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. Germany Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. Germany Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  2. UK
    1. UK Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. UK Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. UK Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. UK Market, By Application
      1. By Research Application
      2. By Clinical Application
  3. France
    1. France Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. France Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. France Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. France Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  4. Spain
    1. Spain Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. Spain Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. Spain Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. Spain Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  5. Italy
    1. Italy Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. Italy Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. Italy Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. Italy Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  6. BENELUX
    1. BENELUX Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. BENELUX Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. BENELUX Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. BENELUX Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  7. Rest of Europe
    1. Rest Of Europe Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. Rest Of Europe Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. Rest Of Europe Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. Rest Of Europe Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
Asia Pacific Cancer Profiling Market - Segment Analysis
1. Overview
2. Asia Pacific Cancer Profiling Market, 2016 - 2028 (USD Million)
3. Asia Pacific Cancer Profiling Market, by Technology
  1. By Immunoassays
  2. By Next-Generation Sequencing
  3. By Polymerase Chain Reaction
  4. By Mass Spectrometry
  5. By In-Situ Hybridization
  6. By Microarrays
  7. By Other Technologies
4. Asia Pacific Cancer Profiling Market, by Cancer Type
  1. By Breast Cancer
  2. By Lung Cancer
  3. By Colorectal Cancer
  4. By Prostate Cancer
  5. By Melanoma Cancer
  6. By Other Cancer
5. Asia Pacific Cancer Profiling Market, by Biomarker Type
  1. By Genomic Biomarker
  2. By Protein Biomarker
  3. By Other Biomarker
6. Asia Pacific Cancer Profiling Market, by Application
  1. By Research Application
  2. By Clinical Application
7. Asia Pacific Cancer Profiling Market, by Country
  1. China
    1. China Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. China Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. China Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. China Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  2. Japan
    1. Japan Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. Japan Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. Japan Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. Japan Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  3. India
    1. India Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. India Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. India Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. India Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  4. South Korea
    1. South Korea Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. South Korea Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. South Korea Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. South Korea Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  5. South East Asia
    1. South East Asia Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. South East Asia Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. South East Asia Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. South East Asia Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  6. Rest of Asia Pacific
    1. Rest of Asia Pacific Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. Rest of Asia Pacific Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. Rest of Asia Pacific Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. Rest of Asia Pacific Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
Latin America Cancer Profiling Market - Segment Analysis
1. Overview
2. Latin America Cancer Profiling Market, 2016 - 2028 (USD Million)
3. Latin America Cancer Profiling Market, by Technology
  1. By Immunoassays
  2. By Next-Generation Sequencing
  3. By Polymerase Chain Reaction
  4. By Mass Spectrometry
  5. By In-Situ Hybridization
  6. By Microarrays
  7. By Other Technologies
4. Latin America Cancer Profiling Market, by Cancer Type
  1. By Breast Cancer
  2. By Lung Cancer
  3. By Colorectal Cancer
  4. By Prostate Cancer
  5. By Melanoma Cancer
  6. By Other Cancer
5. Latin America Cancer Profiling Market, by Biomarker Type
  1. By Genomic Biomarker
  2. By Protein Biomarker
  3. By Other Biomarker
6. Latin America Cancer Profiling Market, by Application
  1. By Research Application
  2. By Clinical Application
7. Latin America Cancer Profiling Market, by Country
  1. Brazil
    1. Brazil Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. Brazil Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. Brazil Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. Brazil Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  2. Argentina
    1. Argentina Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. Argentina Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. Argentina Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. Argentina Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  3. Rest of Latin America
    1. Rest of Latin America Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. Rest of Latin America Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. Rest of Latin America Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. Rest of Latin America Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
Middle East & Africa Cancer Profiling Market - Segment Analysis
1. Overview
2. Middle East & Africa Cancer Profiling Market, 2016 - 2028 (USD Million)
3. Middle East & Africa Cancer Profiling Market, by Technology
  1. By Immunoassays
  2. By Next-Generation Sequencing
  3. By Polymerase Chain Reaction
  4. By Mass Spectrometry
  5. By In-Situ Hybridization
  6. By Microarrays
  7. By Other Technologies
4. Middle East & Africa Cancer Profiling Market, by Cancer Type
  1. By Breast Cancer
  2. By Lung Cancer
  3. By Colorectal Cancer
  4. By Prostate Cancer
  5. By Melanoma Cancer
  6. By Other Cancer
5. Middle East & Africa Cancer Profiling Market, by Biomarker Type
  1. By Genomic Biomarker
  2. By Protein Biomarker
  3. By Other Biomarker
6. Middle East & Africa Cancer Profiling Market, by Application
  1. By Research Application
  2. By Clinical Application
7. Middle East & Africa Cancer Profiling Market, by Country
  1. GCC Countries
    1. GCC Countries Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. GCC Countries Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. GCC Countries Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. GCC Countries Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  2. South Africa
    1. South Africa Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. South Africa Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. South Africa Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. South Africa Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
  3. Rest of Middle East & Africa
    1. Rest of Middle East & Africa Cancer Profiling Market, By Technology
      1. By Immunoassays
      2. By Next-Generation Sequencing
      3. By Polymerase Chain Reaction
      4. By Mass Spectrometry
      5. By In-Situ Hybridization
      6. By Microarrays
      7. By Other Technologies
    2. Rest of Middle East & Africa Cancer Profiling Market, By Cancer Type
      1. By Breast Cancer
      2. By Lung Cancer
      3. By Colorectal Cancer
      4. By Prostate Cancer
      5. By Melanoma Cancer
      6. By Other Cancer
    3. Rest of Middle East & Africa Cancer Profiling Market, By Biomarker Type
      1. By Genomic Biomarker
      2. By Protein Biomarker
      3. By Other Biomarker
    4. Rest of Middle East & Africa Cancer Profiling Market, By Application
      1. By Research Application
      2. By Clinical Application
Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Marketing Stratagy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Competative Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Company Profiles
1. Illumina Inc. (U.S.)
2. QIAGEN (Germany)
3. NeoGenomics Laboratories Inc. (U.S.)
4. HTG Molecular Diagnostics Inc. (U.S.)
5. Genomic Health Inc. (U.S.)
6. Caris Life Sciences (U.S.)
7. Helomics Corporation (U.S.)
8. NanoString Technologies Inc. (U.S.)
9. Sysmex Corporation (Japan)
10. Ribomed Biotechnologies Inc. (U.S.)
11. Guardant Health Inc. (U.S.)
12. Foundation Medicine (U.S.) Roche Diagnostics (Switzerland)
13. (U.S.)
14. GenScript Biotech Corporation (China)
15. Tempus Labs (U.S.)
16. Boreal Genomics Inc (Canada)
17. Perthera (U.S.)
18. Agendia (U.S.)
19. Omniseq (U.S.) Histogene X (Belgium)
Key Primary Respondents - VERBATIM
Discussion Guide
Customization Offered
Annexure
List of Figures
List of Tables
List of Abbreviations

Vantage Market Research | 27-Apr-2023

Cancer Profiling Market to Reach Valuation of USD 19.28 Billion by 2030 – Growth in The Microbiome Effects and The Rising Prevalence of Cancer Cases Drive the Market

FAQ

Frequently Asked Question

What is the global demand for Cancer Profiling in terms of revenue?

The global Cancer Profiling valued at USD 9.4 Billion in 2022 and is expected to reach USD 19.28 Billion in 2030 growing at a CAGR of 10.8%.

Which are the prominent players in the market?

The prominent players in the market are Illumina Inc. (U.S.), QIAGEN (Germany), NeoGenomics Laboratories Inc. (U.S.), HTG Molecular Diagnostics Inc. (U.S.), Genomic Health Inc. (U.S.), Caris Life Sciences (U.S.), Helomics Corporation (U.S.), NanoString Technologies Inc. (U.S.), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (U.S.), Guardant Health, Inc. (U.S.), Foundation Medicine (U.S.) Roche Diagnostics (Switzerland), (U.S.), GenScript Biotech Corporation (China), Tempus Labs (U.S.), Boreal Genomics Inc (Canada), Perthera (U.S.), Agendia (U.S.), Omniseq (U.S.) Histogene X (Belgium).

At what CAGR is the market projected to grow within the forecast period?

The market is project to grow at a CAGR of 10.8% between 2023 and 2030.

What are the driving factors fueling the growth of the market.

The driving factors of the Cancer Profiling include
- Rising incidence of cancer

Which region accounted for the largest share in the market?

North America was the leading regional segment of the Cancer Profiling in 2022.

Cancer Profiling Market

Cancer Profiling Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Cancer Profiling in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Vantage Market Research

Products & Services

Media

Contact Us

Cancer Profiling Market

Cancer Profiling Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Cancer Profiling in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Related Reports

Request Sample Report for Cancer Profiling Market

Vantage Point Interactive Dashboard